CNS targeted delivery of anti-HIV drugs

描述（由申请人提供）：本项目计划开发一种药物递送系统，该系统提供最大药物暴露并抑制大脑和中枢神经系统（CNS）组织中残留的人类免疫缺陷病毒（HIV）*。高活性抗逆转录病毒联合药物疗法（HAART）的出现已将血浆病毒浓度降低到无法检测的水平，并延长了HIV+受试者的预期寿命。然而，CNS组织中的残留病毒，经历有限的药物暴露，与neuroAIDS疾病进展有关。与华盛顿大学合作，Impel NeuroPharma开发了一种新技术，该技术将克服有限的CNS药物获取，从而允许最大限度的药物暴露和病毒抑制。这种技术不是将药物沉积到鼻细胞（用传统的鼻腔递送装置实现），而是将药物沉积在嗅觉细胞中，并提供直接进入大脑和CNS的途径，从而提高CNS递送的效率。拟议中的UW合作将使Impel能够进一步优化和开发这种将抗HIV药物输送到大脑和CNS中的设备，并在适当的动物模型中对其进行评估。我们设想该产品将用于抑制CNS中的病毒，作为当前口服HARRT的辅助药物，其可有效抑制血液中的HIV。[* 缩略语列表附在参考文献末尾]公共卫生相关性：拟议的华盛顿大学合作研究将允许Impel NeuroPharma，Inc进一步优化和开发该器械，用于将抗HIV药物输送到大脑和CNS中，并在适当的临床前模型中对其进行评价。我们设想该产品将用于抑制CNS中的病毒，作为当前口服HARRT的辅助药物，其可有效抑制血液中的HIV。

DESCRIPTION (provided by applicant): This program plans to develop a drug delivery system that provides maximum drug exposure and suppress residual human immunodeficiency virus (HIV)* in the brain and tissues of central nervous system (CNS). The advent of highly active antiretroviral combination drug therapies (HAART) has reduced plasma virus concentration to undetectable level and has extended life-expectancy in HIV+ subjects. However, residual virus in the CNS tissues, experiencing limited drug exposure is related to neuroAIDS disease progression. In collaboration with University of Washington, Impel NeuroPharma has developed a novel technology that will overcome limited CNS drug access thereby allowing a maximum drug exposure and viral suppression. Instead of depositing drugs to nasal cells (achieved with traditional nasal delivery devices), this technology deposits drugs in olfactory cells and provides direct access to the brain and CNS, thereby improving the efficiency of CNS delivery. The proposed UW collaboration will allow Impel to further optimize and develop this device for delivery of anti-HIV drugs into the brain and CNS and evaluating it in appropriate animal models. We envisioned that this product will be used to suppress virus in the CNS as an adjunct to the current oral HARRT, which are effective for suppressing HIV in blood. [*Abbreviation list is enclosed at the end of references] PUBLIC HEALTH RELEVANCE: The proposed University of Washington collaborative research will allow Impel NeuroPharma, Inc to further optimize and develop this device for delivery of anti-HIV drugs into the brain and CNS and evaluating it in appropriate preclinical models. We envisioned that this product will be used to suppress virus in the CNS as an adjunct to the current oral HARRT, which are effective for suppressing HIV in blood.